Sheller on American Law Journal TV discussing FDA and Pharma Executives,
The American Law Journal 2013-06-16 Attorney Stephen Sheller sparred with pharmaceutical defense attorney Hope Freiwald of Dechert law firm on the television program The American Law Journal. The attorneys, joined by Pharmalot author Ed Silverman, Atlanta pharmaceutical product liability attorney Matthew Harman in a program moderated by attorney Christopher Naughton discussed the FDA and drug […]
Sheller in Philadelphia Inquirer “High Court Sides with Philadelphia Drug Firm”
2013-06-25 In a case involving a Philadelphia company, a divided U.S. Supreme Court ruled Monday that federal pharmaceutical laws preempt a person’s ability to sue in state court alleging that a generic drug is designed badly and therefore is dangerous. The court’s 5-4 decision in Mutual Pharmaceutical Co. v. Bartlett is a victory for the […]
SuperLawyers 2013: seven Sheller, P.C. attorneys honored
2013-05-17 [pdf-embedder url=”http://sheller.com/wp-content/uploads/2013/05/Sheller_PASLRS13_FINAL.pdf”] The law firm of Sheller, P.C. announces the selection of six attorneys as Pennsylvania SuperLawyers® and one as Pennsylvania Rising Star for 2013. Stephen A. Sheller is once again honored for the tenth straight year, and for the fourth year as a Top 100 Philadelphia and Top 100 Pennsylvania SuperLawyers®. Also for […]
Temple Times on Sheller Center for Social Justice
2013-02-15 [pdf-embedder url=”http://sheller.com/wp-content/uploads/2015/07/Temple_Times_story_Sheller_Center_for_Social_Justice_2_15_13.pdf”] Featured story: “Sheller Family Foundation’s $1.5 million gift to Temple Law will establish Social Justice Center” Stephen and Sandra Sheller, who have spent their respective careers in law and behavioral health treatment advocating for the poor, powerless and those experiencing injustice, have made a $1.5 million gift to establish a new […]
Sheller Gift Establishes Social Justice Center at Temple University Beasley School of Law
Sheller in Forbes.com “Will A Court Ruling Usher In Off-Label Promotions?”
2012-12-31 [pdf-embedder url=”http://sheller.com/wp-content/uploads/2015/07/SH_Forbes_Quote_SAS_12_12.pdf”] A U.S. Appeals Court ruling that pitted free speech rights versus off-label promotion of pharmaceuticals has raised speculation that 2013 may usher in the sort of aggressive marketing by drug makers that has previously drawn the wrath of federal prosecutors.
Sheller Risperdal settlements front page Legal Intelligencer
2012-10-05 The first trial in which evidence was taken in the mass tort litigation over Risperdal, the antipsychotic drug that plaintiffs have claimed causes males to grow breasts, was settled as part of a group of five cases that resolved this week for undisclosed amounts, according to the plaintiffs’ lawyers and a statement from the […]
J&J agrees to settle five Risperdal suits
2012-10-04 Sheller attorneys announce that five Risperdal cases have been settled for confidential amounts. “Our clients are very pleased,” Steve Sheller, a plaintiffs’ attorney, said in a Bloomberg report after the settlement was announced. “I’ll never be truly satisfied because of what happened here with these kids. It’s a sad commentary on what goes on […]
Sheller Client’s Mother Asks Judge in Risperdal Trial to Release J&J Report for Jurors
Philadelphia Inquirer 2012-09-28 Public companies file documents with the U.S. Securities and Exchange Commission all the time, and the chief executive officer signs them to say they are true. Shareholders and others can look at the statements at sec.gov. But showing particular documents to a jury is not so automatic. On Thursday, attorneys representing a […]
J&J Settles with Sheller client on first day of Risperdal jury trial
Bloomberg BusinessWeek 2012-09-10 – Johnson & Johnson (JNJ) settled a lawsuit on the first day of a trial over claims its antipsychotic drug Risperdal caused a male plaintiff to grow breast tissue, one of his lawyers told a state judge in Philadelphia. Visit this page for up to date national and regional news coverage on Sheller, P.C.’s representation […]
